Telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development, a recent article reads. SS Innovations CEO Dr. Sudhir Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. The company reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations. The company’s installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets.
The growing interest in telerobotic surgery is putting SS Innovations International (NASDAQ: SSII) and its founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, in an increasingly relevant part of the surgical robotics market. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery while the… Read More>>
The significance of these developments lies in the broader implications for global healthcare. Telerobotic surgery could address surgeon shortages and enable expert care in remote or underserved regions. SS Innovations’ growing procedure volume and international expansion demonstrate that remote surgery is becoming clinically viable. However, widespread adoption hinges on regulatory clearances in major markets like the U.S. and Europe. The company’s pursuit of FDA clearance and CE marking is critical; success would validate its technology and open significant market opportunities. As the MedTech Dive article suggests, the question is whether the U.S. will embrace telerobotic surgery. If it does, SS Innovations is well-positioned to benefit, given its existing telesurgery experience. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. For investors, the company’s progress in telesurgery and its expanding installed base signal potential for growth in the surgical robotics market. As remote procedures gain ground, SS Innovations’ early mover advantage and clinical data could set it apart from competitors.
